case_images: PMC10716271_01
case_images: Clinical photographs of the patient at baseline showing erythema and ichthyosis linearis circumflexa like scales over the abdomen (A), back (B), thighs (C), chest (D).
case_images: fped-11-1297658-g001.jpg
case_images: PMC10716271_01_fped-11-1297658-g001.jpg
case_images: F1
case_images: Cutaneous examination revealed generalised erythema and scaling in the form of ichthyosis linearis circumflexa (ILC) (Figure 1).
case_images: Clinical photographs of the patient after receiving 8 doses of subcutaneous secukinumab showing marked reduction in erythema and scaling over the abdomen (A), back (B), thighs (C), chest (D).
case_images: fped-11-1297658-g002.jpg
case_images: PMC10716271_01_fped-11-1297658-g002.jpg
case_images: F2
case_images: Significant improvement in disease severity in terms of pruritus as well as erythema and scaling could be observed after 8 doses (4 months) of secukinumab therapy (Figures 2A-2D).
case_images: Relative mRNA expression of cytokine genes from patient before and after anti-IL17A therapy.
case_images: fped-11-1297658-g003.jpg
case_images: PMC10716271_01_fped-11-1297658-g003.jpg
case_images: F3
case_images: To assess the efficacy of anti-IL17 therapy, mRNA expression of Th17 related pathway genes were checked at three different time points (Figure 3). Th17 pathways were examined (Figure 3). The relative mRNA expression of the IL17A (6.45-fold; p = 0.001), IL21 (1.45-fold; p = 0.014), and IL22 (2.08-fold; p = 0.21) cytokines were elevated at first time points (before first dose of injection).
case_images: Assessment of CD4+-T helper cell population in whole blood received from patient before and after anti-IL17A therapy.
case_images: fped-11-1297658-g004.jpg
case_images: PMC10716271_01_fped-11-1297658-g004.jpg
case_images: F4
case_images: Assessment of CD4+-T helper cell population in whole blood received from patient before and after anti-IL17A therapy (Figure 4). T-helper cell subtypes were assessed by flowcytometry techniques (Figure 4).